Alembic Pharmaceuticals enters into development and license agreement with ABP

Alembic Pharmaceuticals has entered into a development and license agreement with Accu Break Pharmaceuticals, Inc, USA (ABP) to develop new brand products that will use ABP’s innovative ACCU break tablet technologies. The first product that ABP will seek Food and Drug Administration marketing approval for is an Accu-Break-formatted version of the popular anticoagulant medication warfarin.

Further, ABP’s patented Accu Break tablets can be split easily by hand into exact smaller doses to provide maximum flexibility, and to make it easier and safer for patients and caregivers to adjust their doses.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.